EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of HER2 ‐low expression on the efficacy of endocrine therapy with or without CDK4 /6 inhibitor in HR ‐positive/ HER2 ‐negative metastatic breast cancer: A prospective study

Yun Wu, Hongnan Mo, Hangcheng Xu, Yan Wang, Jiayu Wang, Fei Ma iD, Binghe Xu iD

Thoracic Cancer · 2024-04 · 15 (12) · 965-973

DOI: 10.1111/1759-7714.15282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 13.03.2024. Verfasst von Yun Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CDK4/6 inhibitors in combination with traditional endocrine therapy (ET) have become the recommended first‐line therapy for HR‐positive/HER2‐negative metastatic breast cancer (MBC). The aim of this prospective study was to evaluate the relationship between HER2‐low expression and clinical outcomes in HR‐positive/HER2‐negative MBC patients receiving ET with or without CDK4/6 inhibitors.

Methods

Between April 2016 and November 2019, 233 women with HR‐positive/HER2‐negative MBC who received ET with or without CDK4/6 inhibitors were enrolled into the study. The primary endpoint was progression‐free survival (PFS). Statistical analysis included descriptive statistics, Kaplan–Meier curves, and Cox proportional hazards models.

Results

HER2‐low and HER2‐zero subgroups in the CDK4/6 inhibitor plus ET cohort showed no significant difference in the median PFS (10.9 vs. 8.0 months; hazard ratio: 0.92; 95% confidence interval [CI]: 0.64–1. 30; p = 0.65), while HER2‐low subgroup showed a significantly shorter median PFS compared to the HER2‐zero subgroup in the ET alone cohort (5.6 vs. 17.0 months; hazard ratio: 2.82; 95% CI: 1.34–5.93; p = 0.0044). Moreover, the objective response rate was significantly lower in the HER2‐low subgroup than the HER2‐zero subgroup in the ET alone cohort (10.5% vs. 40.0%, p = 0.047). Lastly, no significant difference was observed in the overall survival between the HER2‐low and HER2‐zero subgroups in both cohorts.

Conclusion

This study suggested that HER2‐low expression may predict the efficacy of ET but not that of CDK4/6 inhibitor plus ET in HR‐positive/HER2‐negative MBC patients. The results of this study highlight the importance of integrating HER2 status in tailoring personalized treatment strategies for HR‐positive MBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6HumansFemaleProspective StudiesMiddle AgedAgedAdultProtein Kinase InhibitorsAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Metastasis

Stichwörter der Autor:innen

CDK4/6 inhibitorsHER2‐lowendocrine therapymetastatic breast cancerprospective analysis

Substanzen

Erb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsERBB2 protein, humanCDK4 protein, humanCDK6 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Fei Ma, Binghe Xu

Förderung

  • National Key Research and Development Program of China
  • CAMS Innovation Fund for Medical Sciences

Zitieren

APA

Wu, Y., Mo, H., Xu, H., Wang, Y., Wang, J., Ma, F., & Xu, B. (2024). Impact of HER2 ‐low expression on the efficacy of endocrine therapy with or without CDK4 /6 inhibitor in HR ‐positive/ HER2 ‐negative metastatic breast cancer: A prospective study. Thoracic Cancer, 15(12), 965-973. https://doi.org/10.1111/1759-7714.15282

Vancouver

Wu Y, Mo H, Xu H, Wang Y, Wang J, Ma F, et al. Impact of HER2 ‐low expression on the efficacy of endocrine therapy with or without CDK4 /6 inhibitor in HR ‐positive/ HER2 ‐negative metastatic breast cancer: A prospective study. Thoracic Cancer. 2024;15(12):965-973. doi:10.1111/1759-7714.15282

BibTeX
@article{Wu2024,
  author = {Wu, Yun and Mo, Hongnan and Xu, Hangcheng and Wang, Yan and Wang, Jiayu and Ma, Fei and Xu, Binghe},
  title = {Impact of HER2 ‐low expression on the efficacy of endocrine therapy with or without CDK4 /6 inhibitor in HR ‐positive/ HER2 ‐negative metastatic breast cancer: A prospective study},
  journal = {Thoracic Cancer},
  year = {2024},
  volume = {15},
  number = {12},
  pages = {965--973},
  doi = {10.1111/1759-7714.15282}
}
Kostenlos starten →